Abstract
In men, prostate cancer is the most common non-cutaneous malignancy and the second most common cause of cancer death. Skeletal complications occur at various points during the disease course, either due to bone metastases directly, or as an unintended consequence of androgen deprivation therapy (ADT). Bone metastases are associated with pathologic fractures, spinal cord compression, and bone pain and can require narcotics or palliative radiation for pain relief. ADT results in bone loss and fragility fractures. This review describes the biology of bone metastases, skeletal morbidity, and recent advances in bone-targeted therapies to prevent skeletal complications of prostate cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 533-546 |
Number of pages | 14 |
Journal | Urologic Clinics of North America |
Volume | 39 |
Issue number | 4 |
DOIs | |
State | Published - Nov 2012 |
Keywords
- ADT
- Bone
- Prostate cancer
- Side effects of therapy
- Skeletal complications
- Skeletal related events
ASJC Scopus subject areas
- Urology